caffeine has been researched along with alpha-synuclein in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kachroo, A; Schwarzschild, MA | 1 |
| Dmitriev, O; Kakish, J; Lee, JS; Nokhrin, S; Tavassoly, O | 1 |
| Kardani, J; Roy, I | 1 |
| Jakova, E; Lee, JS | 1 |
| Delamarre, A; Meissner, WG | 1 |
| Junn, E; Mouradian, MM; Oh, S; Park, ES; Park, HJ; Stock, JB; Voronkov, M; Yan, R; Zhang, J; Zheng, H | 1 |
| Bezdicek, O; Dall'Antonia, I; Dostalova, S; Dusek, P; Friedrich, L; Ibarburu Lorenzo Y Losada, V; Kemlink, D; Nepozitek, J; Nikolai, T; Perinova, P; Prihodova, I; Ruml, M; Ruzicka, E; Sonka, K | 1 |
| Bramanti, P; Mazzon, E; Schepici, G; Silvestro, S | 1 |
2 review(s) available for caffeine and alpha-synuclein
| Article | Year |
|---|---|
Epidemiology, environmental risk factors and genetics of Parkinson's disease.
Topics: Age Distribution; Age of Onset; alpha-Synuclein; Caffeine; Causality; Gene-Environment Interaction; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Mutation; Oxidative Stress; Parkinson Disease; Pesticides; Polymorphism, Single Nucleotide; Prevalence; Risk Factors; Sex Distribution; Smoking; Uric Acid | 2017 |
Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.
Topics: Alkaloids; alpha-Synuclein; Animals; Caffeine; Clinical Trials as Topic; Dopamine; Dopaminergic Neurons; Humans; Neuroprotective Agents; Parkinson Disease | 2020 |
6 other study(ies) available for caffeine and alpha-synuclein
| Article | Year |
|---|---|
Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; alpha-Synuclein; Animals; Caffeine; Disease Models, Animal; Gene Deletion; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neuroprotective Agents; Parkinson Disease; Receptor, Adenosine A2A | 2012 |
The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease.
Topics: alpha-Synuclein; Binding Sites; Biological Products; Caffeine; Calorimetry; Drug Discovery; Humans; Molecular Conformation; Nanopores; Nicotine; Nuclear Magnetic Resonance, Biomolecular; Parkinson Disease; Protein Folding; Structure-Activity Relationship | 2014 |
Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Caffeine; Cell Survival; Drug Evaluation, Preclinical; Erythrocytes; Humans; Oxidation-Reduction; Oxidative Stress; Parkinsonian Disorders; Protein Aggregates; Rats; Reactive Oxygen Species; Recombinant Proteins; Saccharomyces cerevisiae | 2015 |
Behavior of α-synuclein-drug complexes during nanopore analysis with a superimposed AC field.
Topics: alpha-Synuclein; Caffeine; Electricity; Electrophoresis; Humans; Metformin; Models, Chemical; Nanopores; Nicotine; Parkinson Disease; Pharmaceutical Preparations | 2017 |
Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB.
Topics: alpha-Synuclein; Animals; Brain; Caffeine; Coffee; Disease Models, Animal; Fatty Acids; Lewy Body Disease; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Neuroprotection; Parkinson Disease; Phosphorylation; Protein Phosphatase 2; Serotonin | 2018 |
Simultaneous tonic and phasic REM sleep without atonia best predicts early phenoconversion to neurodegenerative disease in idiopathic REM sleep behavior disorder.
Topics: Aged; alpha-Synuclein; Biomarkers; Caffeine; Data Collection; Female; Humans; Male; Middle Aged; Muscle Hypotonia; Neurodegenerative Diseases; Polysomnography; REM Sleep Behavior Disorder; ROC Curve; Sleep, REM; Synucleinopathies | 2019 |